Merck’s Brunello trial hit its primary endpoint for a trispecific diabetic macular edema (DME) program, reflecting clinical benefit for the drug candidate acquired in a $3 billion transaction. The win elevates the development priority for the treatment in a high-need retina market. The endpoint achievement matters commercially because DME treatments compete on dosing frequency, durability, and visual outcomes measured in ophthalmic trials. A pivotal positive readout can shift expectations for regulatory filings and reimbursement trajectories. This update also highlights how large-scale deals are being validated through trial milestones, with post-acquisition assets increasingly driving near-term catalysts for Big Pharma portfolios. For the biotech ecosystem, the Brunello success is a reminder that late-stage ophthalmology remains a fertile space for high-value therapeutics even as competition from existing injectable and implant-based therapies continues.